2. Academic Validation
  3. Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B

Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B

  • Carcinogenesis. 2012 Dec;33(12):2548-57. doi: 10.1093/carcin/bgs283.
Xiang Li 1,  Haitao Li,  Shengqing Li,  Feng Zhu,  Dong Joon Kim,  Hua Xie,  Yan Li,  Janos Nadas,  Naomi Oi,  Tatyana A Zykova,  Dong Hoon Yu,  Mee-Hyun Lee,  Myoung Ok Kim,  Lei Wang,  Weiya Ma,  Ronald A Lubet,  Ann M Bode,  Ziming Dong,  Zigang Dong
Affiliations

Affiliation

  • 1 The Hormel Institute, University of Minnesota, Austin, Minnesota, USA.
PMID: 22962305 DOI: 10.1093/carcin/bgs283
Abstract

Ceftriaxone, an FDA-approved third-generation cephalosporin Antibiotic, has antimicrobial activity against both gram-positive and gram-negative organisms. Generally, ceftriaxone is used for a variety of infections such as community-acquired pneumonia, meningitis and gonorrhea. Its primary molecular targets are the penicillin-binding proteins. However, Other activities of ceftriaxone remain unknown. Herein, we report for the first time that ceftriaxone has antitumor activity in vitro and in vivo. Kinase profiling results predicted that Aurora B might be a potential 'off' target of ceftriaxone. Pull-down assay data confirmed that ceftriaxone could bind with Aurora B in vitro and in A549 cells. Furthermore, ceftriaxone (500 µM) suppressed anchorage-independent cell growth by targeting Aurora B in A549, H520 and H1650 lung Cancer cells. Importantly, in vivo xenograft animal model results showed that ceftriaxone effectively suppressed A549 and H520 lung tumor growth by inhibiting Aurora B. These data suggest the Anticancer efficacy of ceftriaxone for the treatment of lung cancers through its inhibition of Aurora B.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z